{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:45:18Z","timestamp":1794638718346,"version":"4.9.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014989","name":"The Chan Zuckerberg Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014989","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.neurot.2026.e00866","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T22:11:49Z","timestamp":1773353509000},"page":"e00866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lafora disease gene therapy: EPM2A but not EPM2B overexpression results in Lafora body formation"],"prefix":"10.1016","volume":"23","author":[{"given":"Esther O.","family":"Alao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrnaz","family":"Sheibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ummay","family":"Marriam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doretha","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahba","family":"Kasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Nitschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Nitschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmistha","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berge A.","family":"Minassian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neurot.2026.e00866_bib1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/2470","article-title":"Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy","volume":"20","author":"Minassian","year":"1998","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00866_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/ng1238","article-title":"Mutations in NHLRC1 cause progressive myoclonus epilepsy","volume":"35","author":"Chan","year":"2003","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00866_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0887-8994(00)00276-9","article-title":"Lafora's disease: towards a clinical, pathologic, and molecular synthesis","volume":"25","author":"Minassian","year":"2001","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.neurot.2026.e00866_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2025.110654","article-title":"The 9th annual Lafora science symposium: a rare epilepsy community makes progress towards clinical readiness","volume":"171","author":"Williams","year":"2025","journal-title":"Epilepsy Behav"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00866_bib5","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.ymthe.2024.05.032","article-title":"Gene therapy for Lafora disease in the Epm2a(-\/-) mouse model","volume":"32","author":"Zafra-Puerta","year":"2024","journal-title":"Mol Ther"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00866_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70514","article-title":"Advances in gene therapy for Lafora disease: intravenous recombinant adeno-associated virus-mediated delivery of EPM2A and EPM2B genes","volume":"15","author":"Zafra-Puerta","year":"2025","journal-title":"Clin Transl Med"},{"issue":"24","key":"10.1016\/j.neurot.2026.e00866_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262411930","article-title":"Adeno-Associated virus-based gene therapy for lafora disease in Epm2b-Deficient mice","volume":"26","author":"Zafra-Puerta","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00866_bib8","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s44318-024-00339-3","article-title":"Glycogen synthase GYS1 overactivation contributes to glycogen insolubility and malto-oligoglucan-associated neurodegenerative disease","volume":"44","author":"Nitschke","year":"2025","journal-title":"EMBO J"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00866_bib9","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.celrep.2019.04.017","article-title":"Skeletal muscle glycogen chain length correlates with insolubility in mouse models of polyglucosan-associated neurodegenerative diseases","volume":"27","author":"Sullivan","year":"2019","journal-title":"Cell Rep"},{"issue":"49","key":"10.1016\/j.neurot.2026.e00866_bib10","doi-asserted-by":"crossref","first-page":"33816","DOI":"10.1074\/jbc.M807428200","article-title":"Abnormal metabolism of glycogen phosphate as a cause for Lafora disease","volume":"283","author":"Tagliabracci","year":"2008","journal-title":"J Biol Chem"},{"issue":"49","key":"10.1016\/j.neurot.2026.e00866_bib11","doi-asserted-by":"crossref","first-page":"19262","DOI":"10.1073\/pnas.0707952104","article-title":"Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo","volume":"104","author":"Tagliabracci","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"33","key":"10.1016\/j.neurot.2026.e00866_bib12","doi-asserted-by":"crossref","first-page":"25372","DOI":"10.1074\/jbc.M110.148668","article-title":"Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin","volume":"285","author":"DePaoli-Roach","year":"2010","journal-title":"J Biol Chem"},{"issue":"Pt 3","key":"10.1016\/j.neurot.2026.e00866_bib13","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/brain\/awt353","article-title":"The phosphatase activity of laforin is dispensable to rescue Epm2a-\/- mice from Lafora disease","volume":"137","author":"Gayarre","year":"2014","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00866_bib14","doi-asserted-by":"crossref","first-page":"906","DOI":"10.15252\/emmm.201707608","article-title":"Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease","volume":"9","author":"Nitschke","year":"2017","journal-title":"EMBO Mol Med"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00866_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107271","article-title":"Impaired malin expression and interaction with partner proteins in Lafora disease","volume":"300","author":"Skurat","year":"2024","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00866_bib16","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049802","article-title":"Laforin targets malin to glycogen in Lafora progressive myoclonus epilepsy","volume":"16","author":"Mitra","year":"2023","journal-title":"Dis Model Mech"},{"issue":"24","key":"10.1016\/j.neurot.2026.e00866_bib17","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1073\/pnas.0503285102","article-title":"Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin","volume":"102","author":"Gentry","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00866_bib18","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/mt.2008.171","article-title":"Self-complementary AAV vectors; advances and applications","volume":"16","author":"McCarty","year":"2008","journal-title":"Mol Ther"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00866_bib19","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/hmg\/11.11.1251","article-title":"Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice","volume":"11","author":"Ganesh","year":"2002","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00866_bib20","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ana.22156","article-title":"Glycogen hyperphosphorylation underlies lafora body formation","volume":"68","author":"Turnbull","year":"2010","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00866_bib21","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s13311-021-01040-7","article-title":"Targeting Gys1 with AAV-SaCas9 decreases pathogenic polyglucosan bodies and neuroinflammation in adult polyglucosan body and Lafora disease mouse models","volume":"18","author":"Gumusgoz","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00866_bib22","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s13311-022-01218-7","article-title":"AAV-mediated artificial miRNA reduces pathogenic polyglucosan bodies and neuroinflammation in adult polyglucosan body and lafora disease mouse models","volume":"19","author":"Gumusgoz","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2026.e00866_bib23","article-title":"Intracerebroventricular and intravascular injection of viral particles and fluorescent microbeads into the neonatal brain","volume":"113","author":"Kawasaki","year":"2016","journal-title":"J Vis Exp"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00866_bib24","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/emmm.201100174","article-title":"Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease","volume":"3","author":"Valles-Ortega","year":"2011","journal-title":"EMBO Mol Med"},{"issue":"43","key":"10.1016\/j.neurot.2026.e00866_bib25","doi-asserted-by":"crossref","first-page":"14698","DOI":"10.1074\/jbc.RA120.015061","article-title":"Sensitive quantification of alpha-glucans in mouse tissues, cell cultures, and human cerebrospinal fluid","volume":"295","author":"Nitschke","year":"2020","journal-title":"J Biol Chem"},{"issue":"3-4","key":"10.1016\/j.neurot.2026.e00866_bib26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/hum.2022.163","article-title":"Biodistribution of adeno-associated virus gene therapy following cerebrospinal fluid-directed administration","volume":"34","author":"Chen","year":"2023","journal-title":"Hum Gene Ther"},{"issue":"1-2","key":"10.1016\/j.neurot.2026.e00866_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0378-1119(02)00878-8","article-title":"Generation of a synthetic mammalian promoter library by modification of sequences spacing transcription factor binding sites","volume":"297","author":"Tornoe","year":"2002","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00866_bib28","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s12035-019-01842-z","article-title":"Reactive glia-derived neuroinflammation: a novel hallmark in Lafora progressive myoclonus epilepsy that progresses with age","volume":"57","author":"Lahuerta","year":"2020","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.neurot.2026.e00866_bib29","article-title":"The biochemical dynamics of the glycogen phosphatase laforin directly impact brain metabolism","author":"Brewer","year":"2025","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00866_bib30","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41582-018-0057-0","article-title":"Lafora disease - from pathogenesis to treatment strategies","volume":"14","author":"Nitschke","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"S2","key":"10.1016\/j.neurot.2026.e00866_bib31","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1684\/epd.2016.0842","article-title":"Lafora disease","volume":"18","author":"Turnbull","year":"2016","journal-title":"Epileptic Disord"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00866_bib32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00401-024-02698-x","article-title":"Myofiber-type-dependent 'boulder' or 'multitudinous pebble' formations across distinct amylopectinoses","volume":"147","author":"Mitra","year":"2024","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00866_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002037","article-title":"PTG depletion removes lafora bodies and rescues the fatal epilepsy of Lafora disease","volume":"7","author":"Turnbull","year":"2011","journal-title":"PLoS Genet"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00866_bib34","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ana.24104","article-title":"PTG protein depletion rescues malin-deficient Lafora disease in mouse","volume":"75","author":"Turnbull","year":"2014","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00866_bib35","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s13311-023-01434-9","article-title":"Gys1 antisense therapy prevents disease-driving aggregates and epileptiform discharges in a lafora disease mouse model","volume":"20","author":"Donohue","year":"2023","journal-title":"Neurotherapeutics"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00866_bib36","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1093\/brain\/awab194","article-title":"Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease","volume":"144","author":"Ahonen","year":"2021","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00866_bib37","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cmet.2019.07.002","article-title":"Targeting pathogenic lafora bodies in lafora disease using an antibody-enzyme fusion","volume":"30","author":"Brewer","year":"2019","journal-title":"Cell Metab"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00866_bib38","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1021\/acs.molpharmaceut.9b00396","article-title":"Central nervous system delivery and biodistribution analysis of an antibody-enzyme fusion for the treatment of lafora disease","volume":"16","author":"Austin","year":"2019","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00866_bib39","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/mt.2009.292","article-title":"Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB)","volume":"18","author":"Gray","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2026.e00866_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2020.146832","article-title":"Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies","volume":"1739","author":"Bailey","year":"2020","journal-title":"Brain Res"},{"key":"10.1016\/j.neurot.2026.e00866_bib41","article-title":"First-in-human high dose AAV9 intrathecal gene therapy for paediatric CLN7 disease: a phase 1, open-label, single ascending dose, non-randomised clinical trial","volume":"123","author":"Greenberg","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.neurot.2026.e00866_bib42","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.omtm.2020.12.006","article-title":"Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning","volume":"20","author":"Nonnenmacher","year":"2021","journal-title":"Mol Ther, Methods Clin Dev"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00866_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011953","article-title":"Structural basis of the recognition of adeno-associated virus by the neurological system-related receptor carbonic anhydrase IV","volume":"20","author":"Zhang","year":"2024","journal-title":"PLoS Pathog"},{"issue":"9-10","key":"10.1016\/j.neurot.2026.e00866_bib44","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41434-024-00466-w","article-title":"Characterization of brain transduction capability of a BBB-penetrant AAV vector in mice, rats and macaques reveals differences in expression profiles","volume":"31","author":"Bunuales","year":"2024","journal-title":"Gene Ther"},{"issue":"6701","key":"10.1016\/j.neurot.2026.e00866_bib45","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.adm8386","article-title":"An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery","volume":"384","author":"Huang","year":"2024","journal-title":"Science"},{"issue":"13-14","key":"10.1016\/j.neurot.2026.e00866_bib46","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1089\/hum.2021.255","article-title":"Single-dose intrathecal dorsal root ganglia toxicity of onasemnogene abeparvovec in cynomolgus monkeys","volume":"33","author":"Tukov","year":"2022","journal-title":"Hum Gene Ther"},{"issue":"15-16","key":"10.1016\/j.neurot.2026.e00866_bib47","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1089\/hum.2020.167","article-title":"Adeno-associated virus-induced dorsal root ganglion pathology","volume":"31","author":"Hordeaux","year":"2020","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00866_bib48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2131\/jts.46.57","article-title":"Development challenges associated with rAAV-based gene therapies","volume":"46","author":"Bolt","year":"2021","journal-title":"J Toxicol Sci"},{"key":"10.1016\/j.neurot.2026.e00866_bib49","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.omtm.2022.01.013","article-title":"Characterization of AAV-mediated dorsal root ganglionopathy","volume":"24","author":"Buss","year":"2022","journal-title":"Mol Ther, Methods Clin Dev"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00866_bib50","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman Primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00866_bib51","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/hmg\/ddh130","article-title":"Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy","volume":"13","author":"Chan","year":"2004","journal-title":"Hum Mol Genet"},{"issue":"18","key":"10.1016\/j.neurot.2026.e00866_bib52","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1093\/hmg\/ddi306","article-title":"Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy","volume":"14","author":"Lohi","year":"2005","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00866_bib53","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1042\/BJ20141555","article-title":"Biophysical characterization of laforin-carbohydrate interaction","volume":"473","author":"Dias","year":"2016","journal-title":"Biochem J"},{"issue":"41","key":"10.1016\/j.neurot.2026.e00866_bib54","doi-asserted-by":"crossref","first-page":"30412","DOI":"10.1074\/jbc.M606117200","article-title":"Laforin, a dual specificity phosphatase that dephosphorylates complex carbohydrates","volume":"281","author":"Worby","year":"2006","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00866_bib55","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.tcb.2006.06.001","article-title":"Myotubularin phosphatases: policing 3-phosphoinositides","volume":"16","author":"Robinson","year":"2006","journal-title":"Trends Cell Biol"},{"issue":"22","key":"10.1016\/j.neurot.2026.e00866_bib56","doi-asserted-by":"crossref","first-page":"5559","DOI":"10.1016\/j.cell.2021.10.001","article-title":"Glycogen accumulation and phase separation drives liver tumor initiation","volume":"184","author":"Liu","year":"2021","journal-title":"Cell"},{"issue":"30","key":"10.1016\/j.neurot.2026.e00866_bib57","doi-asserted-by":"crossref","first-page":"25650","DOI":"10.1074\/jbc.M111.331611","article-title":"Increased laforin and laforin binding to glycogen underlie lafora body formation in malin-deficient Lafora disease","volume":"287","author":"Tiberia","year":"2012","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00866_bib58","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1093\/brain\/awab182","article-title":"Engineered microRNA-based regulatory element permits safe high-dose miniMECP2 gene therapy in Rett mice","volume":"144","author":"Sinnett","year":"2021","journal-title":"Brain"},{"issue":"569","key":"10.1016\/j.neurot.2026.e00866_bib59","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba9188","article-title":"MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates","volume":"12","author":"Hordeaux","year":"2020","journal-title":"Sci Transl Med"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792600036X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792600036X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:05:03Z","timestamp":1781640303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792600036X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S187874792600036X"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00866","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lafora disease gene therapy: EPM2A but not EPM2B overexpression results in Lafora body formation","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00866","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00866"}}